Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Biogen initiated with an Equal Weight at Wells Fargo » 16:27
12/08/21
12/08
16:27
12/08/21
16:27
BIIB

Biogen

$234.71 /

+7.81 (+3.44%)

Wells Fargo analyst Mohit…

Wells Fargo analyst Mohit Bansal initiated coverage of Biogen with an Equal Weight rating and $250 price target. The analyst thinks does not think a positive national coverage decision would change the growth trajectory of Aducanumab. BAN2401 data in in the second half of 2022 is the single most important catalyst for Biogen shares, says Bansal, who sees the stock moving to $345-$475 upon success and $180 to $190 on failure.

ShowHide Related Items >><<
BIIB Biogen
$234.71 /

+7.81 (+3.44%)

BIIB Biogen
$234.71 /

+7.81 (+3.44%)

12/06/21 Goldman Sachs
Biogen initiated with a Neutral at Goldman Sachs
11/30/21 Wedbush
Wedbush keeps Neutral rating on Biogen after court denies appeal in patent case
11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
BIIB Biogen
$234.71 /

+7.81 (+3.44%)

BIIB Biogen
$234.71 /

+7.81 (+3.44%)

BIIB Biogen
$234.71 /

+7.81 (+3.44%)

BIIB Biogen
$234.71 /

+7.81 (+3.44%)

Periodicals
Biogen weighs restructuring, had plan to acquire Neurocrine in 2019, STAT says » 09:06
12/08/21
12/08
09:06
12/08/21
09:06
BIIB

Biogen

$226.91 /

+2.92 (+1.30%)

, NBIX

Neurocrine

$82.31 /

+1.68 (+2.08%)

In a report detailing how…

In a report detailing how Biogen (BIIB) CEO Michel Vounatsos pushed out head scientist Al Sandrock over challenges with its Alzheimer's drug Aduhelm, STAT's Adam Feuerstein and Damian Garde say Biogen is considering a restructuring plan that will terminate more than 1,000 employees and attempt to save $500M to $750M. They note this would be the largest restructuring in Biogen's history. In addition, STAT reveals that Biogen had a plan to acquire Neurocrine Biosciences (NBIX) in 2019 that did not come to fruition. Reference Link

ShowHide Related Items >><<
NBIX Neurocrine
$82.31 /

+1.68 (+2.08%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

12/06/21 Goldman Sachs
Biogen initiated with a Neutral at Goldman Sachs
11/30/21 Wedbush
Wedbush keeps Neutral rating on Biogen after court denies appeal in patent case
11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
NBIX Neurocrine
$82.31 /

+1.68 (+2.08%)

08:26 Today Oppenheimer
Neurocrine price target raised to $154 from $140 at Oppenheimer
06:23 Today Citi
Neurocrine price target raised to $129 from $127 at Citi
11/18/21 BMO Capital
Neurocrine initiated with an Underperform at BMO Capital
11/17/21
Fly Intel: Top five analyst upgrades
NBIX Neurocrine
$82.31 /

+1.68 (+2.08%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

NBIX Neurocrine
$82.31 /

+1.68 (+2.08%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

Hot Stocks
Sage Therapeutics, Biogen announce new data from LANDSCAPE clinical program » 06:32
12/08/21
12/08
06:32
12/08/21
06:32
SAGE

Sage Therapeutics

$39.60 /

+2.07 (+5.52%)

, BIIB

Biogen

$226.91 /

+2.92 (+1.30%)

Sage Therapeutics (SAGE)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SAGE Sage Therapeutics
$39.60 /

+2.07 (+5.52%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

SAGE Sage Therapeutics
$39.60 /

+2.07 (+5.52%)

11/18/21 Mizuho
Sage Therapeutics price target lowered to $44 from $52 at Mizuho
11/03/21 H.C. Wainwright
Sage Therapeutics price target lowered to $55 from $80 at H.C. Wainwright
11/02/21 RBC Capital
Sage Therapeutics price target lowered to $48 from $52 at RBC Capital
11/02/21 Piper Sandler
Sage's change to CORAL trial increases odds of approval, says Piper Sandler
BIIB Biogen
$226.91 /

+2.92 (+1.30%)

12/06/21 Goldman Sachs
Biogen initiated with a Neutral at Goldman Sachs
11/30/21 Wedbush
Wedbush keeps Neutral rating on Biogen after court denies appeal in patent case
11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
SAGE Sage Therapeutics
$39.60 /

+2.07 (+5.52%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

SAGE Sage Therapeutics
$39.60 /

+2.07 (+5.52%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

BIIB Biogen
$226.91 /

+2.92 (+1.30%)

Monday
Initiation
Biogen initiated with a Neutral at Goldman Sachs » 05:40
12/06/21
12/06
05:40
12/06/21
05:40
BIIB

Biogen

$223.60 /

-4.74 (-2.08%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter initiated coverage of Biogen with a Neutral rating and $271 price target. The company's launch of Aduhelm for Alzheimer's disease "is facing a trifecta of headwinds," with Centers for Medicare and Medicaid Services' upcoming national coverage determination "representing an overhang," Richter tells investors in a research note. A positive outcome of coverage to indication or coverage with restrictions could "ameliorate payor pushback," but physician concerns on Aduhelm's benefit/risk profile and nascent hospital infrastructure need to be resolved for Biogen to realize the commercial opportunity, says the analyst. Richter adds that with a base business under pressure, she's monitoring the ability of Biogen's pipeline to offset declining revenue.

ShowHide Related Items >><<
BIIB Biogen
$223.60 /

-4.74 (-2.08%)

BIIB Biogen
$223.60 /

-4.74 (-2.08%)

11/30/21 Wedbush
Wedbush keeps Neutral rating on Biogen after court denies appeal in patent case
11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
BIIB Biogen
$223.60 /

-4.74 (-2.08%)

BIIB Biogen
$223.60 /

-4.74 (-2.08%)

BIIB Biogen
$223.60 /

-4.74 (-2.08%)

BIIB Biogen
$223.60 /

-4.74 (-2.08%)

Over a week ago
Hot Stocks
Viatris announces appeals court upholds invalidation of Biogen Tecfidera patent » 07:04
12/01/21
12/01
07:04
12/01/21
07:04
VTRS

Viatris

$12.32 /

-0.19 (-1.52%)

, BIIB

Biogen

$235.67 /

-0.68 (-0.29%)

Viatris (VTRS) announced…

Viatris (VTRS) announced that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of West Virginia invalidating Biogen's (BIIB) Tecfidera patent, U.S. Patent No. 8,399,514, for lack of written description. The company launched the first therapeutically equivalent substitutable generic to Tecfidera in August 2020.

ShowHide Related Items >><<
VTRS Viatris
$12.32 /

-0.19 (-1.52%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

VTRS Viatris
$12.32 /

-0.19 (-1.52%)

06/15/21 Citi
Viatris initiated with a Neutral at Citi
04/06/21 RBC Capital
Viatris transferred with an Outperform at RBC Capital
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
03/12/21 Piper Sandler
Viatris price target lowered to $16 from $17 at Piper Sandler
BIIB Biogen
$235.67 /

-0.68 (-0.29%)

11/30/21 Wedbush
Wedbush keeps Neutral rating on Biogen after court denies appeal in patent case
11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
VTRS Viatris
$12.32 /

-0.19 (-1.52%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

VTRS Viatris
$12.32 /

-0.19 (-1.52%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

Hot Stocks
Sage Therapeutics and Biogen report positive data on depression disorder drug » 06:34
12/01/21
12/01
06:34
12/01/21
06:34
SAGE

Sage Therapeutics

$38.85 /

+0.24 (+0.62%)

, BIIB

Biogen

$235.67 /

-0.68 (-0.29%)

Sage Therapeutics (SAGE)…

Sage Therapeutics (SAGE) and Biogen (BIIB) announced 12-month data for the cohort of patients who received zuranolone 50 mg once nightly for 14-days as their initial dose in the ongoing Phase 3 open-label SHORELINE Study and had the opportunity to be followed for 12-months. The SHORELINE Study, part of the LANDSCAPE clinical program, was designed to naturalistically follow adult patients with major depressive disorder - MDD - and evaluate the safety and tolerability of zuranolone as well as the need for repeat dosing for up to one year. For the primary endpoint of safety and tolerability, the data analyzed to date show zuranolone was generally well-tolerated, with no new safety findings or trends identified in the long-term safety data available regardless of the number of courses of zuranolone a patient received. Zuranolone has demonstrated improvements in depressive symptoms and a well-tolerated safety profile throughout the LANDSCAPE clinical program. Secondary endpoints included the percentage of patients who received repeat dosing with zuranolone as well as response and remission as evaluated by the 17-item Hamilton Rating Scale for Depression. In the zuranolone 50 mg cohort, nearly 75% of patients responded to the initial 2-week treatment course. Of those who responded to the initial course and continued in the study, approximately 80% of those patients received at most one additional zuranolone treatment during their time in the study. Enrollment of an anticipated 300 additional patients in the 50 mg cohort is ongoing. The companies plan to present additional data from the ongoing SHORELINE Study in future scientific forums.

ShowHide Related Items >><<
SAGE Sage Therapeutics
$38.85 /

+0.24 (+0.62%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

SAGE Sage Therapeutics
$38.85 /

+0.24 (+0.62%)

11/18/21 Mizuho
Sage Therapeutics price target lowered to $44 from $52 at Mizuho
11/03/21 H.C. Wainwright
Sage Therapeutics price target lowered to $55 from $80 at H.C. Wainwright
11/02/21 RBC Capital
Sage Therapeutics price target lowered to $48 from $52 at RBC Capital
11/02/21 Piper Sandler
Sage's change to CORAL trial increases odds of approval, says Piper Sandler
BIIB Biogen
$235.67 /

-0.68 (-0.29%)

11/30/21 Wedbush
Wedbush keeps Neutral rating on Biogen after court denies appeal in patent case
11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
SAGE Sage Therapeutics
$38.85 /

+0.24 (+0.62%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

SAGE Sage Therapeutics
$38.85 /

+0.24 (+0.62%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

On The Fly
Wall Street in Fives - Must Read Lists for Tuesday » 16:22
11/30/21
11/30
16:22
11/30/21
16:22
REGN

Regeneron

$636.37 /

-17.98 (-2.75%)

, FB

Facebook; also tag MVRS

$324.30 /

-13.525 (-4.00%)

, MVRS

Meta

/

+

, SHOP

Shopify

$1,520.40 /

-48.74 (-3.11%)

, AMZN

Amazon.com

$3,507.58 /

-54.42 (-1.53%)

, $ECON

Economic Data

/

+

, SPY

SPDR S&P 500 ETF Trust

$455.84 /

-8.8 (-1.89%)

, SPX

S&P 500

/

+

, SQ

Square

$208.53 /

-4.46 (-2.09%)

, BYND

Beyond Meat

$70.33 /

-4.23 (-5.67%)

, RKLB

Rocket Lab

$15.90 /

+0.445 (+2.88%)

, DLTR

Dollar Tree

$133.57 /

-7.89 (-5.58%)

, VIR

Vir Biotechnology

$47.39 /

+6.87 (+16.95%)

, LULU

Lululemon

$454.65 /

-9.6 (-2.07%)

, MRNA

Moderna

$353.10 /

-15.085 (-4.10%)

, MRK

Merck

$74.87 /

-0.005 (-0.01%)

, BIIB

Biogen

$235.67 /

-0.68 (-0.29%)

, ZEN

Zendesk

$102.07 /

+6.955 (+7.31%)

, MNTV

Momentive

$20.46 /

-0.67 (-3.17%)

, MEIP

MEI Pharma

$3.44 /

+0.98 (+39.84%)

, IBRX

ImmunityBio

$7.77 /

+1.36 (+21.22%)

, RDHL

RedHill Biopharma

$2.91 /

+0.11 (+3.93%)

, OLMA

Olema Oncology

$8.77 /

-13.19 (-60.06%)

, VIAC

ViacomCBS

$30.93 /

-1.35 (-4.18%)

, VIACA

ViacomCBS

$33.38 /

-1.5 (-4.30%)

, CTRN

Citi Trends

$84.72 /

+6.7 (+8.59%)

, CHS

Chico's

$5.75 /

+0.21 (+3.79%)

, JKS

JinkoSolar

$52.32 /

-3.6 (-6.44%)

, BZUN

Baozun

$13.73 /

-1.1 (-7.42%)

, BNED

Barnes & Noble Education

$7.03 /

-1.865 (-20.97%)

Get caught up quickly on…

ShowHide Related Items >><<
ZEN Zendesk
$102.07 /

+6.955 (+7.31%)

VIR Vir Biotechnology
$47.39 /

+6.87 (+16.95%)

VIAC ViacomCBS
$30.93 /

-1.35 (-4.18%)

SQ Square
$208.53 /

-4.46 (-2.09%)

SPY SPDR S&P 500 ETF Trust
$455.84 /

-8.8 (-1.89%)

SPX S&P 500
/

+

SHOP Shopify
$1,520.40 /

-48.74 (-3.11%)

RKLB Rocket Lab
$15.90 /

+0.445 (+2.88%)

REGN Regeneron
$636.37 /

-17.98 (-2.75%)

RDHL RedHill Biopharma
$2.91 /

+0.11 (+3.93%)

OLMA Olema Oncology
$8.77 /

-13.19 (-60.06%)

MRNA Moderna
$353.10 /

-15.085 (-4.10%)

MRK Merck
$74.87 /

-0.005 (-0.01%)

MNTV Momentive
$20.46 /

-0.67 (-3.17%)

MEIP MEI Pharma
$3.44 /

+0.98 (+39.84%)

LULU Lululemon
$454.65 /

-9.6 (-2.07%)

JKS JinkoSolar
$52.32 /

-3.6 (-6.44%)

IBRX ImmunityBio
$7.77 /

+1.36 (+21.22%)

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

DLTR Dollar Tree
$133.57 /

-7.89 (-5.58%)

CTRN Citi Trends
$84.72 /

+6.7 (+8.59%)

CHS Chico's
$5.75 /

+0.21 (+3.79%)

BZUN Baozun
$13.73 /

-1.1 (-7.42%)

BYND Beyond Meat
$70.33 /

-4.23 (-5.67%)

BNED Barnes & Noble Education
$7.03 /

-1.865 (-20.97%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

$ECON Economic Data
/

+

REGN Regeneron
$636.37 /

-17.98 (-2.75%)

11/30/21 H.C. Wainwright
Regeneron should be bought on today's selloff, says H.C. Wainwright
11/29/21 Morgan Stanley
Morgan Stanley, assuming Omicron becomes dominant, ups Adagio to Overweight
11/18/21 BMO Capital
Regeneron assumed with an Outperform at BMO Capital
11/10/21 Cantor Fitzgerald
Regeneron price target raised to $760 from $700 at Cantor Fitzgerald
FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

11/19/21 JMP Securities
DoubleVerify may see $200M opportunity from Facebook news, says JMP Securities
11/17/21 Goldman Sachs
Amazon named top Americas Internet pick for 2022 at Goldman Sachs
11/09/21 Morgan Stanley
Twitter price target lowered to $62 from $68 at Morgan Stanley
11/09/21 Susquehanna
AMD price target raised to $175 from $145 at Susquehanna
MVRS Meta
/

+

11/08/21 Stifel
AMD-Meta partnership shows secular growth thesis 'gaining momentum,' says Stifel
10/28/21 Piper Sandler
Facebook name change a 'big, bold and risky bet,' says Piper Sandler
SHOP Shopify
$1,520.40 /

-48.74 (-3.11%)

11/24/21 Jefferies
Global-e deal for Flow Commerce strengthens D2C position, says Jefferies
11/15/21
Fly Intel: Top five analyst downgrades
11/15/21 Loop Capital
Shopify downgraded to Hold at Loop Capital on valuation
11/15/21 Loop Capital
Shopify downgraded to Hold from Buy at Loop Capital
AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

11/24/21 JPMorgan
Amazon should surpass Walmart as largest retailer in 2022, says JPMorgan
11/22/21 Guggenheim
Amazon.com assumed with a Buy at Guggenheim
11/19/21 RBC Capital
Williams-Sonoma price target raised to $219 from $199 at RBC Capital
11/18/21 Bernstein
Amazon card news in the U.K. 'clearly a show of strength,' says Bernstein
$ECON Economic Data
/

+

11/22/21 BTIG
In picking Powell, Biden went with 'safest choice,' says BTIG
08/04/21 Citi
Citi sees 10-year yield rising to 2%, cuts 'tech-heavy' U.S. to Neutral
SPY SPDR S&P 500 ETF Trust
$455.84 /

-8.8 (-1.89%)

11/26/21 Morgan Stanley
Covid variant mutations may reduce vaccine effectiveness, says Morgan Stanley
11/26/21 Credit Suisse
Concerns over new Covid variant 'understandable,' says Credit Suisse
SPX S&P 500
/

+

SQ Square
$208.53 /

-4.46 (-2.09%)

11/30/21
Fly Intel: Top five analyst upgrades
11/30/21 BofA
Square upgraded to Neutral from Underperform at BofA
11/30/21 BofA
Square upgraded to Neutral from Underperform at BofA
11/17/21 UBS
Square initiated with a Buy at UBS
BYND Beyond Meat
$70.33 /

-4.23 (-5.67%)

11/30/21
Fly Intel: Top five analyst initiations
11/30/21 HSBC
HSBC starts Beyond Meat with sell on 'increasingly competitive' market
11/29/21 HSBC
Beyond Meat initiated with a Reduce at HSBC
11/15/21 Cowen
Beyond Meat price target lowered to $79 from $101 at Cowen
RKLB Rocket Lab
$15.90 /

+0.445 (+2.88%)

11/30/21 BofA
Rocket Lab initiated with a Buy at BofA
11/30/21 BofA
Rocket Lab initiated with a Buy at BofA
10/04/21 BofA
Astra initiated with an Underperform at BofA
09/30/21 Stifel
Rocket Lab initiated with a Buy at Stifel
DLTR Dollar Tree
$133.57 /

-7.89 (-5.58%)

11/30/21
Fly Intel: Top five analyst downgrades
11/29/21 Goldman Sachs
Goldman Sachs downgrades Dollar Tree to Neutral, ups price target to $150
11/29/21 Goldman Sachs
Dollar Tree downgraded to Neutral from Buy at Goldman Sachs
11/26/21 Morgan Stanley
Dollar Tree 'bull case path' to over $200 'getting clearer,' says Morgan Stanley
VIR Vir Biotechnology
$47.39 /

+6.87 (+16.95%)

11/30/21 H.C. Wainwright
Vir Biotechnology price target raised to $200 from $135 at H.C. Wainwright
11/17/21 Baird
Baird ups Vir Biotechnology target to $36 on new U.S. contract for Sotrovimab
10/25/21
Fly Intel: Top five analyst upgrades
10/25/21 JPMorgan
JPMorgan upgrades Vir to Neutral on estimate upside potential
LULU Lululemon
$454.65 /

-9.6 (-2.07%)

12/01/21 Argus
Lululemon price target raised to $530 from $500 at Argus
11/18/21 Cowen
Cowen lays out top retail picks into strongest holiday in 20 years
11/17/21 B. Riley
Lululemon price target raised to $548 from $466 at B. Riley
10/29/21 JPMorgan
Lululemon price target raised to $570 from $500 at JPMorgan
MRNA Moderna
$353.10 /

-15.085 (-4.10%)

11/28/21 Piper Sandler
Moderna has multiple booster candidates to combat omicron, says Piper Sandler
11/26/21 Piper Sandler
Moderna has been preparing for emergence of new variants, says Piper Sandler
11/23/21 Morgan Stanley
Positive flu vaccine data can drive Moderna 10%-20% higher, says Morgan Stanley
11/19/21 Piper Sandler
Moderna can gain share from Pfizer in booster market, says Piper Sandler
MRK Merck
$74.87 /

-0.005 (-0.01%)

11/29/21
Fly Intel: Top five analyst downgrades
11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 Citi
Merck downgraded to Neutral from Buy at Citi
BIIB Biogen
$235.67 /

-0.68 (-0.29%)

11/30/21 Wedbush
Wedbush keeps Neutral rating on Biogen after court denies appeal in patent case
11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
ZEN Zendesk
$102.07 /

+6.955 (+7.31%)

11/30/21 Craig-Hallum
Zendesk price target lowered to $140 from $150 at Craig-Hallum
11/19/21
Fly Intel: Top five analyst downgrades
11/19/21 Stifel
Zendesk's upcoming deal proxy may help investors gain comfort, says Stifel
11/19/21 Cowen
Zendesk downgraded to Market Perform from Outperform at Cowen
MNTV Momentive
$20.46 /

-0.67 (-3.17%)

11/18/21 Jefferies
Zendesk price target lowered to $110 from $120 at Jefferies
11/16/21 Credit Suisse
Zendesk initiated with a Neutral at Credit Suisse
MEIP MEI Pharma
$3.44 /

+0.98 (+39.84%)

09/09/21 Truist
MEI Pharma price target lowered to $8 from $12 at Truist
09/07/21 Brookline
MEI Pharma price target raised to $20 from $11.50 at Brookline
04/26/21 Wells Fargo
MEI Pharma likely to expand scope of voruciclib development, says Wells Fargo
IBRX ImmunityBio
$7.77 /

+1.36 (+21.22%)

10/19/21 Piper Sandler
Piper says ImmunityBio could have 'blockbuster opportunity' with Anktiva
06/04/21 Piper Sandler
ImmunityBio shared 'positive data points' on N-803 at ASCO, says Piper Sandler
04/07/21 Piper Sandler
ImmunityBio price target raised to $25 from $18 at Piper Sandler
RDHL RedHill Biopharma
$2.91 /

+0.11 (+3.93%)

12/01/21 BTIG
RedHill Biopharma price target lowered to $10 from $16 at BTIG
11/18/21
RedHill Biopharma files to sell common stock, no amount given
09/15/21 BTIG
RedHill Biopharma price target lowered to $16 from $24 at BTIG
09/15/21 H.C. Wainwright
RedHill Biopharma price target lowered to $21 from $23 at H.C. Wainwright
OLMA Olema Oncology
$8.77 /

-13.19 (-60.06%)

10/11/21
Olema Oncology participates in a conference call with JPMorgan
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
12/14/20 JPMorgan
Olema Oncology initiated with an Overweight at JPMorgan
12/14/20 Jefferies
Olema Pharmaceuticals initiated with a Buy at Jefferies
VIAC ViacomCBS
$30.93 /

-1.35 (-4.18%)

10/15/21 Deutsche Bank
ViacomCBS price target lowered to $44 from $45 at Deutsche Bank
08/18/21
Fly Intel: Top five analyst upgrades
08/18/21 Wells Fargo
ViacomCBS upgraded to Overweight from Equal Weight at Wells Fargo
08/06/21
Fly Intel: Top five analyst upgrades
VIACA ViacomCBS
$33.38 /

-1.5 (-4.30%)

01/05/21 Gabelli
ViacomCBS named a best idea for 2021 at Gabelli
CTRN Citi Trends
$84.72 /

+6.7 (+8.59%)

10/28/21
Citi Trends management to meet with Benchmark
09/21/21 Benchmark
Citi Trends initiated with a Buy at Benchmark
08/25/21 Craig-Hallum
Citi Trends price target raised to $165 from $150 at Craig-Hallum
05/26/21 Craig-Hallum
Citi Trends price target raised to $150 from $142 at Craig-Hallum
CHS Chico's
$5.75 /

+0.21 (+3.79%)

06/09/21 B. Riley
Chico's price target raised to $5.25 from $2.50 at B. Riley
03/03/21 B. Riley
Chico's price target raised to $2.50 from $2 at B. Riley Securities
01/15/21 B. Riley
Chico's price target raised to $2 from $1.50 at B. Riley Securities
JKS JinkoSolar
$52.32 /

-3.6 (-6.44%)

11/22/21 GLJ Research
U.S. to imminently appeal bi-facial solar panel decision, says GLJ Research
11/16/21 Roth Capital
Roth says court restoring solar 'bifi' exemption a 'major surprise'
11/15/21 Roth Capital
Roth Capital not expecting A-SMACC to reveal petitioner to keep anti-circ case alive
11/10/21 Roth Capital
Anti-Circ thrown out, incremental negative for First Solar, says Roth Capital
BZUN Baozun
$13.73 /

-1.1 (-7.42%)

12/01/21 Citi
Baozun price target lowered to $19 from $22 at Citi
10/20/21 Citi
Baozun price target lowered to $22 from $34 at Citi
08/20/21 Daiwa
Baozun downgraded to Neutral from Buy at Daiwa
08/20/21 HSBC
Baozun price target lowered to $22 from $38 at HSBC
BNED Barnes & Noble Education
$7.03 /

-1.865 (-20.97%)

ZEN Zendesk
$102.07 /

+6.955 (+7.31%)

VIR Vir Biotechnology
$47.39 /

+6.87 (+16.95%)

VIAC ViacomCBS
$30.93 /

-1.35 (-4.18%)

SQ Square
$208.53 /

-4.46 (-2.09%)

SHOP Shopify
$1,520.40 /

-48.74 (-3.11%)

RKLB Rocket Lab
$15.90 /

+0.445 (+2.88%)

REGN Regeneron
$636.37 /

-17.98 (-2.75%)

RDHL RedHill Biopharma
$2.91 /

+0.11 (+3.93%)

MRNA Moderna
$353.10 /

-15.085 (-4.10%)

MRK Merck
$74.87 /

-0.005 (-0.01%)

MNTV Momentive
$20.46 /

-0.67 (-3.17%)

MEIP MEI Pharma
$3.44 /

+0.98 (+39.84%)

LULU Lululemon
$454.65 /

-9.6 (-2.07%)

JKS JinkoSolar
$52.32 /

-3.6 (-6.44%)

IBRX ImmunityBio
$7.77 /

+1.36 (+21.22%)

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

DLTR Dollar Tree
$133.57 /

-7.89 (-5.58%)

CTRN Citi Trends
$84.72 /

+6.7 (+8.59%)

CHS Chico's
$5.75 /

+0.21 (+3.79%)

BZUN Baozun
$13.73 /

-1.1 (-7.42%)

BYND Beyond Meat
$70.33 /

-4.23 (-5.67%)

BNED Barnes & Noble Education
$7.03 /

-1.865 (-20.97%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

  • 19
    Nov
  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
  • 02
    Mar
  • 23
    Feb
ZEN Zendesk
$102.07 /

+6.955 (+7.31%)

VIR Vir Biotechnology
$47.39 /

+6.87 (+16.95%)

VIAC ViacomCBS
$30.93 /

-1.35 (-4.18%)

SQ Square
$208.53 /

-4.46 (-2.09%)

SPY SPDR S&P 500 ETF Trust
$455.84 /

-8.8 (-1.89%)

SHOP Shopify
$1,520.40 /

-48.74 (-3.11%)

RKLB Rocket Lab
$15.90 /

+0.445 (+2.88%)

REGN Regeneron
$636.37 /

-17.98 (-2.75%)

MVRS Meta
/

+

MRNA Moderna
$353.10 /

-15.085 (-4.10%)

MRK Merck
$74.87 /

-0.005 (-0.01%)

MNTV Momentive
$20.46 /

-0.67 (-3.17%)

LULU Lululemon
$454.65 /

-9.6 (-2.07%)

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

DLTR Dollar Tree
$133.57 /

-7.89 (-5.58%)

BYND Beyond Meat
$70.33 /

-4.23 (-5.67%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

$ECON Economic Data
/

+

ZEN Zendesk
$102.07 /

+6.955 (+7.31%)

VIR Vir Biotechnology
$47.39 /

+6.87 (+16.95%)

VIAC ViacomCBS
$30.93 /

-1.35 (-4.18%)

SQ Square
$208.53 /

-4.46 (-2.09%)

SPY SPDR S&P 500 ETF Trust
$455.84 /

-8.8 (-1.89%)

SHOP Shopify
$1,520.40 /

-48.74 (-3.11%)

RKLB Rocket Lab
$15.90 /

+0.445 (+2.88%)

REGN Regeneron
$636.37 /

-17.98 (-2.75%)

MNTV Momentive
$20.46 /

-0.67 (-3.17%)

LULU Lululemon
$454.65 /

-9.6 (-2.07%)

JKS JinkoSolar
$52.32 /

-3.6 (-6.44%)

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

DLTR Dollar Tree
$133.57 /

-7.89 (-5.58%)

CHS Chico's
$5.75 /

+0.21 (+3.79%)

BYND Beyond Meat
$70.33 /

-4.23 (-5.67%)

BNED Barnes & Noble Education
$7.03 /

-1.865 (-20.97%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

$ECON Economic Data
/

+

VIAC ViacomCBS
$30.93 /

-1.35 (-4.18%)

SQ Square
$208.53 /

-4.46 (-2.09%)

SPY SPDR S&P 500 ETF Trust
$455.84 /

-8.8 (-1.89%)

SPX S&P 500
/

+

SHOP Shopify
$1,520.40 /

-48.74 (-3.11%)

RKLB Rocket Lab
$15.90 /

+0.445 (+2.88%)

REGN Regeneron
$636.37 /

-17.98 (-2.75%)

RDHL RedHill Biopharma
$2.91 /

+0.11 (+3.93%)

MRNA Moderna
$353.10 /

-15.085 (-4.10%)

MRK Merck
$74.87 /

-0.005 (-0.01%)

LULU Lululemon
$454.65 /

-9.6 (-2.07%)

JKS JinkoSolar
$52.32 /

-3.6 (-6.44%)

FB Facebook; also tag MVRS
$324.30 /

-13.525 (-4.00%)

DLTR Dollar Tree
$133.57 /

-7.89 (-5.58%)

BYND Beyond Meat
$70.33 /

-4.23 (-5.67%)

BNED Barnes & Noble Education
$7.03 /

-1.865 (-20.97%)

BIIB Biogen
$235.67 /

-0.68 (-0.29%)

AMZN Amazon.com
$3,507.58 /

-54.42 (-1.53%)

SPY SPDR S&P 500 ETF Trust
$455.84 /

-8.8 (-1.89%)

SPX S&P 500
/

+

Recommendations
Wedbush keeps Neutral rating on Biogen after court denies appeal in patent case » 14:42
11/30/21
11/30
14:42
11/30/21
14:42
BIIB

Biogen

$232.82 /

-3.53 (-1.49%)

Wedbush analyst Laura…

Wedbush analyst Laura Chico notes that the U.S. Court of Appeals has ruled against Biogen in its Tecfidera patent appeal case. The decision arrives far later than expected with the case taking nearly a year following oral arguments to reach a ruling, Chico notes. The analyst believes this seems to remove any possibility of restarting Tecfidera exclusivity in the U.S. and anticipates continued erosion to continue. Against that backdrop, it would seem that Aduhelm is critical to the company's forward strategy, she contends. Chico awaits the CMS National Coverage Determination outcome, but even assuming broad access, she continues to see this as a challenging launch. The analyst keeps a Neutral rating on Biogen with a price target of $261.

ShowHide Related Items >><<
BIIB Biogen
$232.82 /

-3.53 (-1.49%)

BIIB Biogen
$232.82 /

-3.53 (-1.49%)

11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
11/17/21 Piper Sandler
'Hits just keep on coming' for Biogen, says Piper Sandler
BIIB Biogen
$232.82 /

-3.53 (-1.49%)

BIIB Biogen
$232.82 /

-3.53 (-1.49%)

BIIB Biogen
$232.82 /

-3.53 (-1.49%)

BIIB Biogen
$232.82 /

-3.53 (-1.49%)

Periodicals
Biogen denied appeal to revive patent on MS drug, Bloomberg reports » 14:41
11/30/21
11/30
14:41
11/30/21
14:41
BIIB

Biogen

$232.98 /

-3.37 (-1.43%)

Biogen has lost an appeal…

Biogen has lost an appeal bid to revive a key patent on the multiple sclerosis drug Tecfidera, reported Bloomberg's Susan Decker and Christopher Yasiejko. The U.S. Court of Appeals for the Federal Circuit ruled that a trial court was correct when it invalidated a patent on the medicine and the court also affirmed a decision by a review board within the U.S. Patent and Trademark office in a related ruling, Bloomberg said. Reference Link

ShowHide Related Items >><<
BIIB Biogen
$232.98 /

-3.37 (-1.43%)

BIIB Biogen
$232.98 /

-3.37 (-1.43%)

11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
11/17/21 Piper Sandler
'Hits just keep on coming' for Biogen, says Piper Sandler
BIIB Biogen
$232.98 /

-3.37 (-1.43%)

BIIB Biogen
$232.98 /

-3.37 (-1.43%)

BIIB Biogen
$232.98 /

-3.37 (-1.43%)

BIIB Biogen
$232.98 /

-3.37 (-1.43%)

Options
Early notable gainers among liquid option names on November 30th » 09:55
11/30/21
11/30
09:55
11/30/21
09:55
TSLA

Tesla

$1,155.43 /

+19.08 (+1.68%)

, MCHP

Microchip

$85.01 /

+0.49 (+0.58%)

, PFE

Pfizer

$53.07 /

+0.67 (+1.28%)

, DHI

D.R. Horton

$99.74 /

+0.99 (+1.00%)

, BIIB

Biogen

$238.50 /

+2.15 (+0.91%)

Notable gainers among…

Notable gainers among liquid option names this morning include Tesla (TSLA) $1162.42 +25.43, Microchip (MCHP) $85.95 +1.55, Pfizer (PFE) $53.30 +0.91, D R Horton (DHI) $100.35 +1.59, and Biogen (BIIB) $239.70 +3.59.

ShowHide Related Items >><<
TSLA Tesla
$1,155.43 /

+19.08 (+1.68%)

PFE Pfizer
$53.07 /

+0.67 (+1.28%)

MCHP Microchip
$85.01 /

+0.49 (+0.58%)

DHI D.R. Horton
$99.74 /

+0.99 (+1.00%)

BIIB Biogen
$238.50 /

+2.15 (+0.91%)

TSLA Tesla
$1,155.43 /

+19.08 (+1.68%)

11/30/21 GLJ Research
Tesla 'leak' an attempt to lower, then beat, Q4 expectations, says GLJ Research
11/24/21 Morgan Stanley
Morgan Stanley stays Underweight Ford, admits to being wrong after near-double
11/19/21 Morgan Stanley
Apple Car would be 'ultimate EV bear case,' says Morgan Stanley
11/19/21 Wedbush
Tesla price target raised to $1,400 from $1,100 at Wedbush
MCHP Microchip
$85.01 /

+0.49 (+0.58%)

10/27/21 BofA
BofA keeps Buy rating, $225 target on Texas Instruments after Q3 report
10/14/21 Stifel
Microchip initiated with a Hold at Stifel
10/13/21
Fly Intel: Top five analyst initiations
10/13/21 UBS
Microchip initiated with a Neutral at UBS
PFE Pfizer
$53.07 /

+0.67 (+1.28%)

11/29/21 Morgan Stanley
Merck price target lowered to $82 from $88 at Morgan Stanley
11/29/21 Morgan Stanley
Pfizer price target raised to $60 from $50 at Morgan Stanley
11/29/21 JPMorgan
Pfizer price target raised to $53 from $42 at JPMorgan
11/26/21 Citi
Pfizer can deliver novel vaccine within 100 days of sequencing, says Citi
DHI D.R. Horton
$99.74 /

+0.99 (+1.00%)

11/17/21 Raymond James
D.R. Horton price target raised to $120 from $110 at Raymond James
11/11/21 Citi
D.R. Horton price target raised to $116 from $104 at Citi
11/10/21 Barclays
D.R. Horton price target raised to $122 from $109 at Barclays
11/08/21 BofA
D.R. Horton reinstated with a Buy at BofA
BIIB Biogen
$238.50 /

+2.15 (+0.91%)

11/18/21 BMO Capital
Biogen initiated with an Outperform at BMO Capital
11/17/21 Cowen
Cowen says Biogen negative vote at CHMP 'disappointing, but far from surprising'
11/17/21 Stifel
Biogen shares weren't really pricing in Europe approval, says Stifel
11/17/21 Piper Sandler
'Hits just keep on coming' for Biogen, says Piper Sandler
TSLA Tesla
$1,155.43 /

+19.08 (+1.68%)

PFE Pfizer
$53.07 /

+0.67 (+1.28%)

MCHP Microchip
$85.01 /

+0.49 (+0.58%)

DHI D.R. Horton
$99.74 /

+0.99 (+1.00%)

BIIB Biogen
$238.50 /

+2.15 (+0.91%)

TSLA Tesla
$1,155.43 /

+19.08 (+1.68%)

PFE Pfizer
$53.07 /

+0.67 (+1.28%)

MCHP Microchip
$85.01 /

+0.49 (+0.58%)

DHI D.R. Horton
$99.74 /

+0.99 (+1.00%)

BIIB Biogen
$238.50 /

+2.15 (+0.91%)

TSLA Tesla
$1,155.43 /

+19.08 (+1.68%)

PFE Pfizer
$53.07 /

+0.67 (+1.28%)

MCHP Microchip
$85.01 /

+0.49 (+0.58%)

DHI D.R. Horton
$99.74 /

+0.99 (+1.00%)

BIIB Biogen
$238.50 /

+2.15 (+0.91%)

TSLA Tesla
$1,155.43 /

+19.08 (+1.68%)

PFE Pfizer
$53.07 /

+0.67 (+1.28%)

MCHP Microchip
$85.01 /

+0.49 (+0.58%)

DHI D.R. Horton
$99.74 /

+0.99 (+1.00%)

BIIB Biogen
$238.50 /

+2.15 (+0.91%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.